alexa GT198 And Her2 Double Positivity As An Improved Therapeutic Marker For Herceptin Treatment In Human Breast Cancer
ISSN: 2572-4118

Breast Cancer: Current Research
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

5th World Congress on Breast Cancer
June 15-17, 2017 London, UK

Lan Ko, Christopher Harlow and Alistair Williams
Augusta University Cancer Center, USA
University of Edinburgh, UK
Posters & Accepted Abstracts: Breast Can Curr Res
DOI: 10.4172/2572-4118-C1-006
Abstract
Breast cancer is a lethal cancer in women. It is urgent to identify new therapeutic biomarkers to facilitate the treatment. Therapeutic drug Herceptin (trastuzumab) is effective in Her2-positive breast cancer treatment, however, there is inconsistency to distinguish responders versus non-responders using Her2 as a sole biomarker. The human GT198 gene is a breast and ovarian cancer gene at chromosome 17q12, 2.9 Mb proximal from the ERBB2 gene encoding Her2. Both germline mutations and high frequency somatic mutations in GT198 are present in breast and ovarian cancer. In breast and ovarian tumors, somatic mutations are present in tumor stromal stem cells. Gene copy number increase of GT198 has also been found in breast cancer. Here we find that Her2 and GT198 proteins are co-expressed in breast tumor stromal cells carrying GT198 mutations, suggesting that Herceptin may in fact also target GT198-positive tumor stromal cells. Her2 gene amplicons generally encompass large genomic regions, thus the two adjacent genes may co-amplify and result in coexpression. Our finding suggests that GT198/Her2 double positivity is potentially a more specific therapeutic marker for Herceptin. In particular, positive tumor stroma, in addition to tumor, deserves more attention in clinical decisions. Since herceptin is extensively used in the treatment of breast cancer and GT198 is a causative breast cancer gene, this study provides insights into novel mechanisms associated with herceptin efficacy and reveals new biomarker using GT198 for improved targeted therapy.
Biography

Email: [email protected]

image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords